Cat Burton was diagnosed with Behçet's disease in 2013. This rare and poorly understood condition means she suffers from ...

Behçet's disease (BD) is a multisystem inflammatory disorder currently classified as a vasculitis. Its etiopathogenesis is unclear, but environmental, genetic and autoimmune factors have been ...

Soligenix, Inc.  (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...

Furthermore, we expect to report top-line results in the second half of this year from our ongoing Phase 2 studies of SGX945 (dusquetide) in Behçet's disease and SGX302 (synthetic hypericin ...

Discover the essential facts about chancroid, a lesser-known but serious STI that causes painful genital ulcers and increases ...

A powerful new photography exhibition in London sees 100 women paint their scars in gold in a nod to the Japanese art of Kintsugi. Organiser and former A&E doctor Liz Murray explains how she hopes it ...

for oral ulcers associated with Behçet’s disease. Meanwhile, a new subcutaneous formulation of Takeda’s Entyvio (vedolizumab) – currently given as an intravenous infusion – was ...

The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease ...

Chairman and CEO Dr. Christopher Schaber joined IBN’s BioMedWire Podcast to discuss the company’s two-pronged business model, robust late-stage pipeline, and ongoing clinical trials. Schaber ...

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is advancing its phase 3 replication study (“FLASH2”) for HyBryte(TM), a novel photodynamic therapy designed to treat early-stage ...